US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Chervon North America Recalls EGO Power+ Cordless Brushless Hedge Trimmers Due to Laceration Hazard

      The rear switch trigger can fail to rebound after being pressed, which can cause the unit to activate unexpectedly, posing a laceration hazard. … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Urgent Recalls / Sitagliptin – Januvia and Janumet – Type Two Diabetes Drugs and Acute Pancreatitis

Sitagliptin – Januvia and Janumet – Type Two Diabetes Drugs and Acute Pancreatitis

September 25, 2009 By E. Sizemore 3 Comments

type-two-diabetes-drugThe FDA is revising the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these medications for type two diabetes.

Eighty-eight post-marketing cases of acute pancreatitis were reported to the Agency between October 2006 and February 2009. These include two cases of hemorrhagic or necrotizing pancreatitis in patients using sitagliptin.

The FDA recommends that healthcare professionals monitor patients carefully for the development of pancreatitis after initiation or dose increases of sitagliptin or sitagliptin/metformin. Sitagliptin has not been studied in patients with a history of pancreatitis. Therefore, it is not known whether these patients are at an increased risk for developing pancreatitis and the medication should be used with caution and with appropriate monitoring in patients with a history of pancreatitis.

Sitagliptin, the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

FDA is working with the manufacturer of sitagliptin and sitagliptin/metformin to revise the prescribing information to include:

  • Information regarding post-marketing reports of acute pancreatitis, including the severe forms, hemorrhagic or necrotizing pancreatitis.
  • Recommending that healthcare professionals monitor patients carefully for the development of pancreatitis after initiation or dose increases of sitagliptin or sitagliptin/metformin, and to discontinue sitagliptin or sitagliptin/metformin if pancreatitis is suspected while using these products.
  • Information noting that sitagliptin has not been studied in patients with a history of pancreatitis. Therefore, it is not known whether these patients are at an increased risk for developing pancreatitis while using sitagliptin or sitagliptin/metformin. Sitagliptin or sitagliptin/metformin should be used with caution and with appropriate monitoring in patients with a history of pancreatitis.

Considerations for Healthcare Professionals Regarding Sitagliptin (Januvia / Janumet) and Acute Pancreatitis

  • Be aware of the possibility for and monitor for the emergence of the signs and symptoms of pancreatitis such as nausea, vomiting, anorexia, and persistent severe abdominal pain, sometimes radiating to the back.
  • Discontinue sitagliptin or sitagliptin/metformin if pancreatitis is suspected.
  • Understand that if pancreatitis is suspected in a patient, supportive medical care should be instituted. The patient should be monitored closely with appropriate laboratory studies such as serum and urine amylase, amylase/creatinine clearance ratio, electrolytes, serum calcium, glucose, and lipase.
  • Inform patients of the signs and symptoms of acute pancreatitis so they are aware of and able to notify their healthcare professional if they experience any unusual signs or symptoms.

Information for Type Two Diabetes Patients

  • Be aware that acute pancreatitis has been reported in patients using sitagliptin or sitagliptin/metformin.
  • Pay close attention for any signs or symptoms of pancreatitis such as nausea, vomiting, anorexia, and persistent severe abdominal pain, sometimes radiating to the back.
  • Promptly discuss any signs and symptoms of pancreatitis with a healthcare professional.
  • Do not stop or change medicines that have been prescribed without first talking with a knowledgeable healthcare professional.

Background and Data Summary:
FDA has completed a review of 88 cases of acute pancreatitis in patients using sitagliptin or sitagliptin/metformin. The cases were reported to FDA’s Adverse Event Reporting System (AERS) between October 2006 and February 2009. Hospitalization was reported in 58/88 (66%) of the patients, 4 of whom were admitted to the intensive care unit (ICU). Two cases of hemorrhagic or necrotizing pancreatitis were identified in the review and both required an extended stay in the hospital with medical management in the ICU. The most common adverse events reported in the 88 cases were abdominal pain, nausea and vomiting.

Additionally, the analysis found that 19 of the 88 reported cases (21%) of pancreatitis occurred within 30 days of starting sitagliptin or sitagliptin/metformin. Furthermore, 47 of the 88 cases (53%) resolved once sitagliptin was discontinued. It is important to note that 45 cases (51%) were associated with at least one other risk factor for developing pancreatitis, such as diabetes, obesity, high cholesterol and/or high triglycerides.

Based on the temporal relationship of initiating sitagliptin or sitagliptin/metformin and development of acute pancreatitis in the reviewed cases, FDA believes there may be an association between these events. Because acute pancreatitis is associated with considerable morbidity and mortality, and early recognition is important in reducing adverse health outcomes, FDA is recommending revisions to the prescribing information to alert healthcare professionals to this potentially serious adverse drug event.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: Urgent Recalls

About E. Sizemore

Comments

  1. JIM WOFFORD says

    May 18, 2010 at 10:10 pm

    like quinine

    Reply
  2. jack says

    June 4, 2010 at 9:34 am

    Janumet is combination medicine. Has two active ingredients called Sitagliptin Phosphate-Metformin Hydrochloride in 50mg and 500mg dosages. Even generic equivalent of Janumet is now available, you can also find details on this at International Drug Mart.

    Reply
  3. JANICE PAYTON says

    February 17, 2011 at 3:38 am

    THIS DRUG MADE ME SICK, I THOUGH IT WAS THE END FOR ME.

    Reply

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Chervon North America Recalls EGO Power+ Cordless Brushless Hedge Trimmers Due to Laceration Hazard

May 31, 2023 By The CPSC

Jetson Electric Bikes Recalls Nova and Star 3-Wheel Kick Children’s Scooters Due to Fall Hazard

May 31, 2023 By The CPSC

Empower Brands Recalls Power XL Self-Cleaning Juicers Due to Laceration and Ingestion Hazards

May 31, 2023 By The CPSC

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Cricket Creek Farm Recalls Sophelise and Tobasi Cheeses Because of Potential Listeria Monocytogenes Contamination

May 30, 2023 By The FDA

A.S.K. Foods Inc. Issues Allergy Alert on Undeclared Milk In Wegmans Penne Rigate Mozzarella Salad

May 25, 2023 By The FDA

T.W. Garner Food Company Issues Voluntary Recall on Texas Pete® Buffalo Wing Sauce Due to Undeclared Soy

May 24, 2023 By The FDA

Bunch Bikes Recalls The Preschool Electric Bicycles Due to Violation of the Federal Lead Paint Ban; Lead Poisoning Hazard (Recall Alert)

May 24, 2023 By The CPSC

The Good and the Beautiful Recalls Math 1 and Math 3 Boxes Due to Laceration Hazard (Recall Alert)

May 24, 2023 By The CPSC

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Bunch Bikes Recalls The Preschool Electric Bicycles Due to Violation of the Federal Lead Paint Ban; Lead Poisoning Hazard (Recall Alert)

May 24, 2023 By The CPSC

The Good and the Beautiful Recalls Math 1 and Math 3 Boxes Due to Laceration Hazard (Recall Alert)

May 24, 2023 By The CPSC

Juratoys Recalls Children’s Activity Tables Due to Choking Hazard

May 24, 2023 By The CPSC

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Chervon North America Recalls EGO Power+ Cordless Brushless Hedge Trimmers Due to Laceration Hazard
  • Jetson Electric Bikes Recalls Nova and Star 3-Wheel Kick Children’s Scooters Due to Fall Hazard
  • Empower Brands Recalls Power XL Self-Cleaning Juicers Due to Laceration and Ingestion Hazards
  • Rudolph Foods Issues Allergy Alert on Undeclared Wheat in Rudolph’s OnYums “Onion Flavored Rings”, 3 oz. Packages
  • Tillamook Issues Allergy Alert on Undeclared Wheat and Soy in Tillamook Waffle Cone Swirl Ice Cream Packaged in Chocolate Peanut Butter Ice Cream Carton
  • Cricket Creek Farm Recalls Sophelise and Tobasi Cheeses Because of Potential Listeria Monocytogenes Contamination
  • A.S.K. Foods Inc. Issues Allergy Alert on Undeclared Milk In Wegmans Penne Rigate Mozzarella Salad
  • T.W. Garner Food Company Issues Voluntary Recall on Texas Pete® Buffalo Wing Sauce Due to Undeclared Soy
  • Bunch Bikes Recalls The Preschool Electric Bicycles Due to Violation of the Federal Lead Paint Ban; Lead Poisoning Hazard (Recall Alert)
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2023 Altrumedia · Terms of Service · Log in